注射用头孢哌酮钠舒巴坦钠不良反应/事件监测及评价分析

目的探讨注射用头孢哌酮钠舒巴坦钠不良反应/事件（ADR/ADE）的发生规律,为临床安全、合理用药提供参考。方法对2012年5月—2014年4月在本院静脉滴注注射用头孢哌酮钠舒巴坦钠出现ADR/ADE的43例患者的临床资料进行回顾性分析。结果注射用头孢哌酮钠舒巴坦钠ADR/ADE与年龄、既往疾病等因素有关,主要发生于〉50岁年龄组中有心血管系统疾病既往病史者;ADR/ADE与联合用药有关,联用药物越多ADR/ADE发生率越高;ADR/ADE主要为一般过敏性反应（皮肤及附件损害）,其次为消化系统、呼吸系统反应等,采取治疗措施后,＂痊愈＂9例,占20.9%;＂好转＂33例,占76.7%;死亡1例,占2.4%,ADR/ADE的转归与既往疾病有关。结论注射用头孢哌酮钠舒巴坦钠ADR/ADE可由用药以外因素（如年龄、既往疾病等）诱发,临床使用须引起高度重视。

Monitoring and Evaluation of Adverse Reactions/Events of Cefoperazone Sodium and Sulbactam Sodium for Injection

Objective To discuss the regularity of adverse reactions/events （ADR/ADE） of Cefoperazone Sodium and Sulbactam Sodium for Injection, to provided reference for safe and rational drug use on clinic. Methods A total of 43 cases occurred ADR/ADE during intravenous drip of Cefoperazone Sodium and Sulbactam Sodium for Injection in our hospital from May 2012 to April 2014 were retrospectively analyzed. Results ADR/ADE of Cefoperazone Sodium and Sulbactam Sodium for Injection was related to age, past medical history, mainly occurred in patients over 50 years old who had cardiovascular diseases; ADR/ADE was related to drug combination, the more drugs, the higher incidence of ADR/ADE; the most ADR/ADE was general allergic reaction （skin damage and accessories damage）, followed by the digestive system, respiratory system; Mter treatment, 9 out of the 43 cases ＂ healed＂, accounted for 20. 9% ; 33 cases ＂ got better ＂, accounted for 76.7% ; 1 case died, accounted for 2.4%. The outcome of ADR/ADE is associated with past diseases. Conclusion ADR/ADE of Cefoperazone Sodium and Sulbactam Sodium for Injection can caused by drug outside factors, such as age, past diseases, which clinical usage should be pay more attention to.